Researchers believe there may be a way to predict which patients are more likely to respond to the experimental drug tivozanib. This is possible, said researchers from AVEO, because they have used a new way of creating animal tumor models that mimic tumor variation seen in human. Based on the results of these studies, they have found a single biomarker that may predict resistance to tivozanib, an oral, triple VEGF receptor inhibitor. Release